Perspectum Announces Partnership with Datavant to Improve Clinical Trial Recruitment with Connected Data
16 sept. 2021 07h00 HE
|
Datavant
SAN FRANCISCO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Perspectum, a global quantitative and genomics-based imaging company, is joining forces with Datavant, the leader in helping healthcare...
Madrigal Pharmaceuticals Reports 2021 Second Quarter Financial Results and Provides Corporate Update
05 août 2021 06h50 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reports today its second quarter 2021 financial results and provides a summary of corporate...
Robert Waltermire Joins Madrigal Pharmaceuticals as Chief Pharmaceutical Development Officer
02 août 2021 06h50 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases...
Madrigal Pharmaceuticals Offers Patients Resmetirom in a Planned Open Label Active Treatment Extension of the Phase 3 MAESTRO-NAFLD-1 Clinical Study
13 juil. 2021 17h47 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., July 13, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its first patient dosed in a planned 52-week open label active treatment extension...
Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver Biopsy Patient Population in the Phase 3 MAESTRO-NASH Study of Resmetirom
30 juin 2021 06h50 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., June 30, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today achievement of the planned target enrollment in the Phase 3 clinical trial,...
Madrigal Pharmaceuticals Announces Presentation of Positive Clinical Data of Resmetirom from Open-Label Portion of Ongoing Phase 3 Clinical Trial MAESTRO-NAFLD-1 at The International Liver Congress™ 2021
25 juin 2021 11h30 HE
|
Madrigal Pharmaceuticals, Inc.
Use of non-invasive measurements demonstrated that resmetirom: was safe and well-tolerated at 100 mg per day in non-cirrhotic NASH patients treated for 52 weeks;provided rapid and sustained...
Non-alcoholic fatty liver disease market worth US$62.06 billion by 2031. Visiongain Research Inc.
08 juin 2021 09h00 HE
|
Visiongain Ltd
Global Non-alcoholic Fatty Liver Disease & NAFLD Market Forecast 2021-2031: -By Disease Cause (Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity, Other Disease Causes) By...
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences
08 juin 2021 06h50 HE
|
Madrigal Pharmaceuticals, Inc.
WEST CONSHOHOCKEN, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical- stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic...
Madrigal Pharmaceuticals to Participate in UBS Global Healthcare Virtual Conference
21 mai 2021 09h38 HE
|
Madrigal Pharmaceuticals, Inc.
WEST CONSHOHOCKEN, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and...
Madrigal Pharmaceuticals to Present at RBC Capital Markets Virtual 2021 Global Healthcare Conference on Wednesday, May 19, 2021 at 8:00 a.m. ET
18 mai 2021 09h00 HE
|
Madrigal Pharmaceuticals, Inc.
WEST CONSHOHOCKEN, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and...